Bristol Myers Squibb and Incyte Lead Big Pharma’s AI Expansion
Daily Biopharma Digest — May 20, 2026
Big pharma is going all-in on AI partnerships as M&A activity and biotech IPOs accelerate. Today’s top developments:
- Bristol Myers Squibb signed a strategic AI collaboration with Anthropic
- Incyte committed $120 million to AI drug development via expanded Genesis collaboration
- Lilly acquired Engage Biologics for up to $202M to bolster non-viral DNA delivery
- Parabilis filed for IPO after raising $800M to pursue ‘undruggable’ targets
- NIH faces a leadership vacuum amid broader HHS turmoil
What to Watch
- AI partnerships proliferate — With Bristol Myers and Incyte deploying major AI collaborations, expect more pharma players to announce similar deals in coming quarters as competitive pressure mounts to demonstrate AI integration.
- IPO window widens — Parabilis’s filing as the 12th biotech IPO this year, with average proceeds above $286M, suggests the public market window remains open for well-funded companies with strategic partnerships.
- Non-viral delivery momentum — Lilly’s $202M Engage acquisition highlights growing pharma interest in alternatives to viral vectors as the genetic medicine field matures beyond early modalities.
- NIH leadership uncertainty — The leadership vacuum at NIH could delay strategic initiatives and grant decisions, creating near-term uncertainty for biotechs dependent on federal research funding.
